Recent Company News

• 04:55 PM ET Jan 20, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 04:34 PM ET Jan 15, 2026
  

  StreetAccount Preannouncement Summary: US Q4 2025

• 04:36 PM ET Jan 13, 2026
  

  FactSet Podcast - Evening Market Recap, 13-Jan

• 04:08 AM ET Jan 05, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:02 AM ET Jan 13, 2026
  

  FDA accepts for priority review sBLA for argenx's VYVGART to treat adults with AChR-Ab seronegative gMG ($796.00, 0.00)

• 12:11 PM ET Jan 12, 2026
  

  Transcript Intelligence: argenx at J.P. Morgan Healthcare Conference ($782.40, -6.09)

• 01:08 AM ET Jan 12, 2026
  

  argenx reports preliminary Q4 global product net sales $1.29B ($788.49, 0.00)

• 02:21 PM ET Jan 06, 2026
  

  StreetAccount Event Preview: Preannouncement Primer for JPM Healthcare Conference